Paul Manning Biography and Net Worth

Director of Acumen Pharmaceuticals

Paul B. Manning is Chairman of the Board of the Company. Mr. Manning is the Chairman and Chief Executive Officer of PBM Capital Group, LLC, a private equity investment firm in the business of investing in healthcare and life-science related companies, which he founded in 2010. Prior to that, Mr. Manning founded PBM Products in 1997, a producer of infant formula and baby food, which was sold to Perrigo Corporation in 2010. Mr. Manning is a director of various private companies. Within the past five years, Mr. Manning previously served on the Board of Directors of Dova Pharmaceuticals, Inc., Perrigo Corporation, Concordia Healthcare Corp. and AveXis, Inc. Mr. Manning received a B.S. in microbiology from the University of Massachusetts. Our Board of Directors believes that Mr. Manning should serve as a director based upon his over 30 years of managerial and operational experience in the healthcare industry and as an investor in healthcare related companies.

What is Paul B. Manning's net worth?: The estimated net worth of Paul B. Manning is at least $1.41 million as of December 16th, 2024. Mr. Manning owns 1,303,752 shares of Acumen Pharmaceuticals stock worth more than $1,408,052 as of April 3rd. This net worth approximation does not reflect any other assets that Mr. Manning may own. Learn More about Paul B. Manning's net worth.
How do I contact Paul B. Manning?: The corporate mailing address for Mr. Manning and other Acumen Pharmaceuticals executives is , , . Acumen Pharmaceuticals can also be reached via phone at 434-297-1000 and via email at investors@acumenpharm.com. Learn More on Paul B. Manning's contact information.
Has Paul B. Manning been buying or selling shares of Acumen Pharmaceuticals?: Paul B. Manning has not been actively trading shares of Acumen Pharmaceuticals in the last ninety days. Most recently, on Tuesday, July 6th, Paul B. Manning bought 312,500 shares of Acumen Pharmaceuticals stock. The stock was acquired at an average cost of $16.00 per share, with a total value of $5,000,000.00. Learn More on Paul B. Manning's trading history.
Who are Acumen Pharmaceuticals' active insiders?: Acumen Pharmaceuticals' insider roster includes Marc Benioff (CEO), Nathan Fountain (Director), Paul Manning (Director), and John Stalfort, III (Director). Learn More on Acumen Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Acumen Pharmaceuticals?: During the last year, insiders at the sold shares 9 times. They sold a total of 131,526 shares worth more than $233,123.83. The most recent insider tranaction occured on January, 23rd when CFO Matt Zuga sold 28,902 shares worth more than $49,711.44. Insiders at Acumen Pharmaceuticals own 7.1% of the company. Learn More about insider trades at Acumen Pharmaceuticals.
Information on this page was last updated on 1/23/2025.

Paul B. Manning Insider Trading History at Acumen Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
7/6/2021	Buy	312,500	$16.00	$5,000,000.00

Paul B. Manning Buying and Selling Activity at Acumen Pharmaceuticals

Acumen Pharmaceuticals Company Overview

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Today's Range

Now: $1.08

$1.05

$1.11

50 Day Range

MA: $1.34

$1.08

$1.73

2 Week Range

Now: $1.08

$1.05

$4.06

Volume

196,930 shs

Average Volume

289,054 shs

Market Capitalization

$64.89 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.02